Humacyte FY2025 EPS Forecast Increased by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA) – Investment analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Humacyte in a report issued on Wednesday, April 23rd. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.71) per share for the year, up from their prior forecast of ($0.95). The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million.

Several other research firms have also commented on HUMA. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

Shares of HUMA opened at $1.44 on Friday. The company has a market capitalization of $223.37 million, a P/E ratio of -1.07 and a beta of 1.62. The business’s 50-day moving average is $2.36 and its two-hundred day moving average is $3.90. Humacyte has a fifty-two week low of $1.15 and a fifty-two week high of $9.97.

Insider Transactions at Humacyte

In related news, CFO Dale A. Sander bought 20,000 shares of the business’s stock in a transaction dated Thursday, April 10th. The stock was acquired at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares of the company’s stock, valued at approximately $62,118. This trade represents a 97.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction that occurred on Tuesday, April 8th. The shares were bought at an average price of $1.32 per share, with a total value of $66,000.00. Following the transaction, the director now owns 91,207 shares in the company, valued at approximately $120,393.24. The trade was a 121.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 83,993 shares of company stock valued at $118,224 in the last three months. 11.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

Several large investors have recently bought and sold shares of the company. Endowment Wealth Management Inc. lifted its position in shares of Humacyte by 3.6% in the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after acquiring an additional 3,590 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Humacyte by 18.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after purchasing an additional 4,327 shares in the last quarter. Beacon Pointe Advisors LLC boosted its stake in Humacyte by 33.3% during the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock worth $101,000 after purchasing an additional 5,000 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Humacyte by 4.6% during the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock worth $578,000 after buying an additional 5,005 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of Humacyte by 25.3% in the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock valued at $132,000 after buying an additional 5,293 shares during the last quarter. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.